The next generation of weight-loss medication may be getting closer.
A large Phase 3 clinical trial published September 29, 2026, in the New England Journal of Medicine found substantial weight loss in adults receiving retatrutide, an investigational medication that acts on three different hormone pathways involved in appetite and metabolism.
At the highest dose, participants lost an average of 25% of their starting body weight over 80 weeks, compared with 3.9% among those receiving placebo. New England Journal of Medicine
That is an impressive result, but it is not the whole story.
Retatrutide is still being studied. It is not currently an FDA-approved weight-loss medication, and the study was funded by its manufacturer, Eli Lilly and Company. Gastrointestinal side effects were common, and we still need longer-term information about what happens during years of treatment and after treatment stops. New England Journal of Medicine
The study also raises a bigger question that extends well beyond one medication:
What are we actually treating when we treat obesity?
Increasingly, the answer is not simply body weight.
Obesity is closely connected with metabolism, sleep, cardiovascular health, joint health, liver health, glucose regulation and other systems throughout the body. The new study provides another example of why weight and metabolic health deserve to be understood together.
What Is Retatrutide?
Retatrutide is a once-weekly injectable medication being studied for the treatment of obesity and related metabolic conditions. It belongs to the same broad family of medications that has changed obesity treatment over the past several years, but it works differently.
Semaglutide acts primarily on a hormone receptor called GLP-1. Tirzepatide acts on GLP-1 and GIP receptors. Retatrutide acts on three hormone receptors: GLP-1, GIP and glucagon. (New England Journal of Medicine)
These hormones participate in appetite, digestion, glucose regulation and energy metabolism. GLP-1 helps signal fullness, slows stomach emptying and influences insulin release. GIP also plays a role in insulin secretion and energy regulation.
Glucagon is often described simply as the hormone that raises blood sugar, but its biology is more complicated. Glucagon signaling also influences the liver and energy metabolism.
Researchers are investigating whether targeting all three pathways together can produce larger metabolic effects than targeting one or two.
That does not automatically mean three is better than two. That is exactly why large clinical trials are needed.
What Did the New Study Do?
TRIUMPH-1 was a Phase 3 randomized, double-blind clinical trial.
That is important because randomized controlled trials provide stronger evidence about whether a treatment causes an outcome than observational studies, where researchers simply watch what happens to people over time.
The study included 2,339 adults with obesity who did not have diabetes.
Participants were randomly assigned to receive a weekly injection of retatrutide at 4 mg, 9 mg or 12 mg, or a placebo, for 80 weeks.
Researchers primarily wanted to know how much body weight changed.
They also studied two groups of participants with common obesity-related conditions: 574 people with knee osteoarthritis and 243 people with obstructive sleep apnea. (New England Journal of Medicine)
How Much Weight Did Participants Lose?
The results were substantial.
After 80 weeks, average body-weight changes in the primary analysis were:
4 mg retatrutide: 17.6% reduction
9 mg retatrutide: 23.7% reduction
12 mg retatrutide: 25.0% reduction
Placebo: 3.9% reduction New England Journal of Medicine
There is an important detail here because you may see a different number reported elsewhere.
Earlier reports from the trial cited average weight loss of 28.3% at 12 mg. That figure comes from an analysis estimating the medication's effect if participants remained on their assigned treatment as intended. The peer-reviewed paper's primary weight analysis counted outcomes more broadly across randomized participants and found 25.0% average weight loss at 12 mg.
Both numbers come from the trial, but they answer slightly different statistical questions. (New England Journal of Medicine)
For patients, the 25% result may be the more useful number to understand because real-world treatment includes people who stop medications or cannot tolerate the full dose.
The Study Was About More Than Weight
One of the most interesting parts of TRIUMPH-1 was what happened beyond the scale.
Researchers specifically studied participants who also had knee osteoarthritis or obstructive sleep apnea.
Osteoarthritis is the gradual breakdown and change of tissue within a joint. Carrying excess weight can increase mechanical stress on weight-bearing joints, but obesity can also influence inflammatory and metabolic pathways related to joint health.
Participants receiving retatrutide experienced greater reductions in knee pain than those receiving placebo. (New England Journal of Medicine)
Researchers also studied obstructive sleep apnea, a condition in which the airway repeatedly becomes blocked during sleep.
Sleep apnea is important because a person can spend enough hours in bed and still experience repeated interruptions in breathing throughout the night. That can affect sleep quality, daytime energy, blood pressure and cardiovascular health.
Among study participants with obstructive sleep apnea, retatrutide significantly reduced the number of apnea and hypopnea events per hour compared with placebo. (New England Journal of Medicine)
These findings do not mean retatrutide should automatically be used to treat everyone with knee pain or sleep apnea. They illustrate something broader. Changing metabolic health can have effects that extend beyond body weight.
Obesity Is Not Simply a Willpower Problem
The success of medications acting on appetite and metabolic hormones has helped challenge an outdated idea about obesity.
Body weight is not controlled by willpower alone.
The brain, gastrointestinal tract, pancreas, liver, fat tissue and hormones communicate continuously to regulate hunger, fullness, glucose and energy use.
Genetics, sleep, medications, hormones, muscle mass, physical activity, food environment and metabolic health all matter. This does not mean nutrition and exercise are unimportant. They remain fundamental components of health. It means the biology determining body weight is considerably more complicated than “eat less and move more.”
But Losing More Weight Is Not Automatically Better
The size of the weight loss in this trial will understandably receive attention. But from a longevity perspective, the most important goal is not necessarily achieving the lowest possible number on the scale.
What happens to body composition matters too.
When someone loses a large amount of weight, some of that weight may come from fat and some may come from lean tissue, including muscle.
Muscle is metabolically active tissue that supports glucose regulation, strength, mobility, physical function and resilience as we age.
That means someone losing significant weight should not necessarily focus only on pounds lost.
We may also want to ask:
Are they maintaining muscle?
Are they eating enough protein and nutrients?
Are they resistance training appropriately?
How is their strength changing?
What is happening to their metabolic health?
How do they feel?
This is where body composition and other objective measurements can add information the scale cannot provide.
What About Side Effects?
The most common adverse effects in the trial involved the gastrointestinal system. These included nausea, diarrhea, constipation and vomiting. Side effects tended to occur more often with higher doses, and some participants discontinued treatment because of adverse events.
An unusual skin sensation called dysesthesia has also been reported in retatrutide trials. Dysesthesia can include sensations such as tingling, burning or unusual sensitivity of the skin. (HCPLive)
These findings are important because treatment decisions are never based only on effectiveness.
The relevant question is not simply, “Does this medication cause weight loss?” It is whether the expected benefits outweigh the risks for a particular person. That requires individualized medical judgment.
Retatrutide Is Not FDA Approved
This point is particularly important because retatrutide has already generated substantial interest online. The September 29 publication reports the results of a Phase 3 clinical trial. It does not represent FDA approval.
Retatrutide remains an investigational medication. Patients should be cautious about products sold online or marketed as retatrutide before regulatory approval. A compound being studied in a pharmaceutical clinical trial is not necessarily the same as a product purchased through an unverified online source.
What We Still Don't Know
TRIUMPH-1 gives us strong evidence that retatrutide can cause substantial weight loss during 80 weeks of treatment in adults with obesity who do not have diabetes.
But important questions remain. We need longer-term safety data. We need to understand what happens to weight, appetite and metabolic health when treatment is stopped. We need more information about preserving muscle and lean mass during very large amounts of weight loss.
And although improvements in metabolic risk factors are encouraging, weight loss itself does not prove that a medication prevents heart attacks, dementia or other major age-related outcomes.
Those questions require their own studies.
The trial was also funded by Eli Lilly, the company developing retatrutide, and several authors were company employees. Industry-funded trials can still provide rigorous evidence, particularly when they are randomized, peer-reviewed Phase 3 studies, but funding and conflicts of interest should always be transparent.
The Bigger Lesson Is About Metabolic Health
The most interesting part of this study may ultimately be bigger than retatrutide. Metabolic health affects far more than weight. It interacts with cardiovascular health, sleep, joint health, liver function, glucose regulation, body composition and the way we age. And many metabolic changes begin before someone feels obviously unwell.
Insulin resistance can develop while glucose still appears acceptable. Body composition can change while body weight remains stable. Cardiovascular fitness can decline before normal daily activities become difficult. Sleep apnea can repeatedly disrupt physiology at night without a person realizing how often it is happening.
This is why Jyzen's approach to metabolic health is not centered on a single number.
Depending on the patient, understanding the bigger picture may involve physician evaluation, laboratory testing, body composition, resting metabolic rate, cardiovascular fitness, glucose data, hormones, sleep and other measures.
Not everyone needs every test. And not everyone needs medication. The goal is to understand the physiology well enough to make thoughtful decisions about what actually deserves attention.
Earlier Understanding Creates More Choices
Retatrutide may eventually become another powerful option for treating obesity. But the larger shift in medicine is already happening.
We are learning to think about obesity as a complex metabolic condition rather than a simple failure of discipline. We are also learning that meaningful improvements in metabolic health can influence systems throughout the body.
At the same time, powerful treatments require careful medical oversight.
A medication that can change body weight by 20% or more is not a casual wellness intervention. Nutrition, muscle preservation, side effects, medications, medical history and long-term health goals all matter.
The goal should never be weight loss at any cost. It should be better health. And the earlier we understand what is changing metabolically, the more choices we have about how to get there.
This article is for educational purposes only and is not individualized medical advice. Retatrutide is investigational and is not currently an FDA-approved weight-loss medication. Decisions about weight-management medications should be made with an appropriately licensed clinician based on individual medical history, risks and treatment goals.
Primary source: Jastreboff AM, Kaplan LM, Davies MJ, et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. New England Journal of Medicine. Published September 29, 2026. DOI: 10.1056/NEJMoa2604169. New England Journal of Medicine